化疗联合卡瑞利珠单抗用于不可手术微卫星稳定型结直肠癌的临床观察

虞伟妃; 汪笑秋; 赵丽萍; 冯继红; 周珏伊

doi:10.6039/j.issn.1001-0408.2023.10.17

您当前的位置：

首页 >

文章列表页 >

化疗联合卡瑞利珠单抗用于不可手术微卫星稳定型结直肠癌的临床观察

药物与临床 | 更新时间：2023-05-25

- 化疗联合卡瑞利珠单抗用于不可手术微卫星稳定型结直肠癌的临床观察
- Clinical observation of chemotherapy combined with camrelizumab in patients with inoperable microsatellite stable type colorectal cancer
- 中国药房 2023年34卷第10期页码：1242-1246
- 作者机构：
  
  丽水市人民医院肿瘤放化疗科，浙江丽水　323000
- 作者简介：
  
  主治医师。研究方向：乳腺癌。E-mail：yuweif123@163.com
  副主任医师。研究方向：临床医学。E-mail：waxiaoq1234@163.com
- 基金信息：
  
  丽水市科技计划项目(2022SJZC032)
- DOI：10.6039/j.issn.1001-0408.2023.10.17
  中图分类号： R979.1
- 纸质出版日期：2023-05-30，
  
  收稿日期：2022-09-20，
  
  修回日期：2023-03-20，
扫描看全文
虞伟妃,汪笑秋,赵丽萍等.化疗联合卡瑞利珠单抗用于不可手术微卫星稳定型结直肠癌的临床观察 ^Δ[J].中国药房,2023,34(10):1242-1246.

YU Weifei,WANG Xiaoqiu,ZHAO Liping,et al.Clinical observation of chemotherapy combined with camrelizumab in patients with inoperable microsatellite stable type colorectal cancer[J].ZHONGGUO YAOFANG,2023,34(10):1242-1246.
虞伟妃,汪笑秋,赵丽萍等.化疗联合卡瑞利珠单抗用于不可手术微卫星稳定型结直肠癌的临床观察 ^Δ[J].中国药房,2023,34(10):1242-1246. DOI： 10.6039/j.issn.1001-0408.2023.10.17.

YU Weifei,WANG Xiaoqiu,ZHAO Liping,et al.Clinical observation of chemotherapy combined with camrelizumab in patients with inoperable microsatellite stable type colorectal cancer[J].ZHONGGUO YAOFANG,2023,34(10):1242-1246. DOI： 10.6039/j.issn.1001-0408.2023.10.17.

摘要

目的

评价XELOX（奥沙利铂+卡培他滨）化疗联合抗血管生成剂（阿帕替尼）和免疫治疗药物（卡瑞利珠单抗）用于不可手术转移性微卫星稳定（MSS）型结直肠癌（CRC）的疗效与安全性。

方法

回顾性收集2020年1月－2021年1月丽水市人民医院收治的40例不可手术转移性MSS型CRC患者的临床资料。根据治疗方案将患者分为对照组（20例）和观察组（20例）。对照组患者接受XELOX+阿帕替尼治疗，观察组患者接受XELOX+阿帕替尼+卡瑞利珠单抗治疗。每3周为1个周期，连续治疗2个周期。记录两组患者的客观缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）和不良事件（AEs）发生情况。

结果

观察组患者的ORR和DCR分别为65.0%、85.0%，对照组患者的ORR和DCR分别为35.0%、75.0%，组间比较差异均无统计学意义（

＞0.05）。观察组和对照组患者的中位PFS分别为16.0、8.0个月，中位OS分别为19.0、12.5个月，组间比较差异均有统计学意义（

＜0.05）。两组患者均至少发生1次AEs，且观察组患者的反应性皮肤毛细血管增生、甲亢的发生率均显著高于对照组（40.0% vs. 0和20% vs. 0，

＜0.05），恶心和呕吐的发生率显著低于对照组（10% vs. 90%，

＜0.05）。观察组患者发生3级及以上AEs的有14例（70.0%），而对照组仅有5例（25.0%），组间比较差异有统计学意义（

＜0.05）。但两组患者均未发生不能耐受或致命的严重AEs，相关症状经停药或接受治疗后均得以缓解。

结论

XELOX化疗联合阿帕替尼和卡瑞利珠单抗用于不可手术转移性MSS型CRC患者的效果与XELOX化疗联合阿帕替尼相当，但具有一定的ORR、PFS和OS优势，且安全性可控。

Abstract

OBJECTIVE

To evaluate the clinical efficacy and safety of XELOX chemotherapy （oxaliplatin+capecitabine） combined with antiangiogenic agent （apatinib） and immunotherapy （camrelizumab） in patients with inoperable metastatic colorectal cancer （CRC）of microsatellite stable （MSS） type.

METHODS

Clinical medical records of 40 patients with inoperable metastatic CRC of MSS type treated in Lishui People’s Hospital from January 2020 to January 2021 were retrospectively collected. According to the treatment plan， the patients were divided into control group （20 cases） and observation group （20 cases）. Control group was given XELOX+apatinib regimen， while observation group was given XELOX+apatinib+camrelizumab regimen. Every 3 weeks was a treatment cycle， and the treatment lasted for 2 consecutive cycles. The objective response rate （ORR）， disease control rate （DCR）， progression-free survival （PFS）， overall survival （OS） and adverse events （AEs） were recorded for all patients.

RESULTS

The ORR and DCR of observation group were 65.0% and 85.0%， respectively； and the ORR and DCR of control group were 35.0% and 75.0%， respectively， with no statistical significance between 2 groups （

＞0.05）. The median PFS of observation group and control groups were 16.0 months and 8.0 months， respectively； and the median OS were 19.0 months and 12.5 months， respectively， with statistical significance between 2 groups （

＜0.05）. Each patient in both groups had at least one AEs， and the incidences of reactive skin capillary hyperplasia and hyperthyroidism in observation group （40.0%， 20.0%） were significantly higher than those in control group （both were 0）（

＜0.05）. The incidence of nausea and vomiting in control group （90%） was significantly higher than observation group （10%）（

＜0.05）. There were 14 cases （70.0%） of patients with grade 3 or above AEs in observation group， and only 5 cases （25.0%） in control group， with statistical significance between 2 groups （

＜0.05）. However， no severe AEs that could not be tolerated or fatal occurred in the two groups， which could be alleviated after drug withdrawal or treatment.

CONCLUSIONS

The efficacy of XELOX chemotherapy combined with apatinib and camrelizumab in inoperable metastatic CRC patients of MSS type is comparable to that of XELOX chemotherapy combined with apatinib， but it has certain advantages in ORR， PFS and OS， and controllable safety.

关键词

不可手术微卫星稳定型转移性结直肠癌化疗免疫治疗抗血管生成剂

Keywords

microsatellite stable typemeta-static colorectal cancerchemotherapyimmunotherapyantiangiogenic agent

references

MODY K，BALDEO C，BEKAII-SAAB T. Antiangiogenic therapy in colorectal cancer[J]. Cancer J，2018，24（4）：165-170.

SIEGEL R L，MILLER K D，JEMAL A. Cancer statistics，2016[J]. CA A Cancer J Clin，2016，66（1）：7-30.

BILLER L H，SCHRAG D. Diagnosis and treatment of metastatic colorectal cancer：a review[J]. JAMA，2021，325（7）：669-685.

PIAWAH S，VENOOK A P. Targeted therapy for colore-ctal cancer metastases：a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer[J]. Cancer，2019，125（23）：4139-4147.

OVERMAN M J，ERNSTOFF M S，MORSE M A. Where we stand with immunotherapy in colorectal cancer： deficient mismatch repair，proficient mismatch repair，and toxicity management[J]. Am Soc Clin Oncol Educ Book，2018，38：239-247.

LIMAGNE E，THIBAUDIN M，NUTTIN L，et al. Trifluridine/tipiracil plus oxaliplatin improves PD-1 blockade in colorectal cancer by inducing immunogenic cell death and depleting macrophages[J]. Cancer Immunol Res，2019，7（12）：1958-1969.

WANG Y Y，WEI B，GAO J H，et al. Combination of fruquintinib and anti-PD-1 for the treatment of colorectal cancer[J]. J Immunol，2020，205（10）：2905-2915.

AKIN TELLI T，BREGNI G，VANHOOREN M，et al. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient（pMMR）/microsa-tellite stable（MSS）colorectal cancer[J]. Cancer Treat Rev，2022，110：102460.

KODAMA H，TERAZAWA T，ISHIZUKA Y，et al. Retrospective comparison of mFOLFOXIRI with XELOX/SOX as neoadjuvant chemotherapy for locally advanced rectal cancer[J]. In Vivo，2021，35（2）：977-985.

GOU H F，ZHOU L，HUANG J，et al. Intraperitoneal oxa-liplatin administration inhibits the tumor immunosuppressive microenvironment in an abdominal implantation model of colon cancer[J]. Mol Med Rep，2018，18（2）：2335-2341.

LI N，ZHU Y，LIU L Y，et al. Postoperative chemoradiotherapy with capecitabine and oxaliplatin vs capecitabine for stage Ⅱ to Ⅲ rectal cancer：a randomized clinical trial[J]. JAMA Netw Open，2021，4（11）：e2136116.

JAVLE M M，OH D Y，IKEDA M，et al. Varlitinib plus capecitabine in second-line advanced biliary tract cancer：a randomized，phase Ⅱ study（TreeTopp）[J]. ESMO Open，2022，7（1）：100314.

LI A Y，WANG K，XU A G，et al. Apatinib as an optional treatment in metastatic colorectal cancer[J]. Medicine（Baltimore），2019，98（35）：e16919.

MARKHAM A，KEAM S J. Camrelizumab：first global approval[J]. Drugs，2019，79（12）：1355-1361.

ZHOU H，WANG Y H，LIN Y F，et al. Preliminary efficacy and safety of camrelizumab in combination with XELOX plus bevacizumab or regorafenib in patients with metastatic colorectal cancer：a retrospective study[J]. Front Oncol，2021，11：774445.

EISENHAUER E A，THERASSE P，BOGAERTS J，et al. New response evaluation criteria in solid tumours：revised RECIST guideline：version 1.1[J]. Eur J Cancer，2009，45（2）：228-247.

FREITES-MARTINEZ A，SANTANA N，ARIAS-SANTIAGO S，et al. Using the common terminology criteria for adverse events （CTCAE-version 5.0） to evaluate the severity of adverse events of anticancer therapies[J]. Actas Dermosifiliogr （Engl Ed），2021，112（1）：90-92.

SIEGEL R，DESANTIS C，JEMAL A. Colorectal cancer statistics，2014[J]. CA Cancer J Clin，2014，64（2）：104-117.

GANESH K，STADLER Z K，CERCEK A，et al. Immunotherapy in colorectal cancer：rationale，challenges and potential[J]. Nat Rev Gastroenterol Hepatol，2019，16（6）：361-375.

LE D T，URAM J N，WANG H，et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med，2015，372（26）：2509-2520.

GAUDREAU P O，NEGRAO M V，MITCHELL K G，et al. Neoadjuvant chemotherapy increases cytotoxic T cell，tissue resident memory T cell，and B cell infiltration in resectable NSCLC[J]. J Thorac Oncol，2021，16（1）：127-139.

LUPO G，CAPORARELLO N，OLIVIERI M，et al. Anti-angiogenic therapy in cancer：downsides and new pivots for precision medicine[J]. Front Pharmacol，2016，7：519.

FUKUMURA D，KLOEPPER J，AMOOZGAR Z，et al. Enhancing cancer immunotherapy using antiangiogenics：opportunities and challenges[J]. Nat Rev Clin Oncol，2018，15（5）：325-340.

LI R R，YIN X L，ZENG D Y，et al. Efficacy and safety of anti-PD-1 antibody plus regorafenib in refractory microsatellite stable metastatic colorectal cancer：a retrospective single-arm cohort study[J]. Ann Transl Med，2022，10（16）：880.

QIN S K，LI Q，GU S Z，et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma（AHELP）：a multicentre，double-blind，randomised，placebo-controlled，phase 3 trial[J]. Lancet Gastroenterol Hepatol，2021，6（7）：559-568.

WANG F，QIN S K，SUN X C，et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocel-lular carcinoma patients treated with camrelizumab：data derived from a multicenter phase 2 trial[J]. J Hematol Oncol，2020，13（1）：47.

CHEN L，JIANG Y Z，WU S Y，et al. Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer（FUTURE-C-plus）：an open-label，single-arm，phase Ⅱ trial[J]. Clin Cancer Res，2022，28（13）：2807-2817.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

小细胞肺癌的临床用药方案现状及潜在靶点药物治疗方案新进展